Significant market opportunities in the Europe at-home respiratory care services sector include growing demand driven by ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary ...

United Therapeutics UTHR remains poised to expand Tyvaso’s label in the respiratory disease space. It recently unveiled results from the late-stage TETON-2 study, which showed clinical benefit in ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present two oral ...

Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Session Title: Innovations in Assessment and Treatment of Fibrosing Lung Disease Session ID: ...